Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

NCT02235701 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Interventions

DRUG: 170 mg/m2 aldoxorubicin
DRUG: 250 mg/m2 aldoxorubicin

Sponsor

ImmunityBio, Inc.